A5083972488- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Psychosomatic Disorders and Their Treatments
- Neurological Disorders and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Vestibular and auditory disorders
- Stroke Rehabilitation and Recovery
- Neuroscience of respiration and sleep
- Long-Term Effects of COVID-19
- Sympathectomy and Hyperhidrosis Treatments
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Dementia and Cognitive Impairment Research
- Hydrogen's biological and therapeutic effects
- Acute Ischemic Stroke Management
- EEG and Brain-Computer Interfaces
- Hepatitis C virus research
- Neural dynamics and brain function
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease Diagnosis and Treatment
- Botulinum Toxin and Related Neurological Disorders
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Neurological Disease Mechanisms and Treatments
- Neurological Complications and Syndromes
- Nuclear Structure and Function
University of Pavia
2021-2025
Urology Foundation
2023-2025
Fondazione Istituto Neurologico Nazionale Casimiro Mondino
2021-2025
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2020
Background Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike many countries have reimbursement policies, which hinder to those who might respond. This study aimed investigate clinical factors associated with good excellent response anti-CGRP MAbs at 6 months. Methods European multicentre, prospective, real-world study, including high-frequency episodic or chronic (CM) patients treated since March 2018...
Coronavirus disease 2019 (COVID-19), a caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become global pandemic. Patients with myasthenia gravis (MG), often treated immunosuppressants, might be at higher risk of developing COVID-19 and demonstrating course. We aimed to study prevalence describe features in MG patients.In May 2020, we conducted telephonic interviews patients followed our referral center. collected structured data regarding COVID-19, which...
Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in treatment of difficult-to-treat patients. In this study, we evaluated psychological predictors outcome with anti-CGRP monoclonal antibody erenumab patients chronic (CM).Seventy-five CM who had already failed at least 3 therapies received every 28 days for a period 12 months. Before...
Migraine is a highly prevalent primary headache disorder and leading cause of disability. Difficulties in access to care during diagnostic therapeutic journey contribute the disease burden. Several target-specific drugs have reached market past four years modified treatment paradigm migraine. The aim this study provide an updated snapshot pathways hurdles for migraine different European countries by directly asking patients.In 2021 Headache Alliance proposed 39-item questionnaire that was...
Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life effectiveness and tolerability. GAINER, prospective, multicentric study, aimed to evaluate rimegepant tolerability real-world setting. Our study involved 16 headache centers across Italy. The main outcomes were: i) 2 h pain freedom, ii) occurrence of...
Background Focusing on calcitonin gene-related peptide (CGRP) as a specific target has changed and improved migraine management. After the positive results of monoclonal antibodies directed to CGRP pathway (anti-CGRP mAbs), randomized controlled trials also demonstrated efficacy gepants in prevention. The present study aimed assess effectiveness atogepant preventing after 12-week treatment clinical practice. Methods Adult patients with indication for 60 mg daily were screened participation...
OnabotulinumtoxinA (BonT-A) reduces migraine frequency in a considerable portion of patients with migraine. So far, predictive characteristics response are lacking. Here, we applied machine learning (ML) algorithms to identify clinical able predict treatment response. We collected demographic and data chronic (CM) or high-frequency episodic (HFEM) treated BoNT-A at our clinic the last 5 years. Patients received according PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therapy)...
miR-155 is involved in the generation and maintenance of inflammation pain, endothelial function immune system homeostasis, all functions that are relevant for migraine. The present study aims to assess levels migraine subtypes (episodic chronic) comparison age- sex-matched healthy controls.
Abstract Background In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) score ≥ 11. Eligibility to continuation requires 50% MIDAS reduction at three months (T3). this study, we evaluate whether T3 is reliable predictor response one-year erenumab treatment. Methods prospective, open-label, real-world 77 CM were treated 70–140 mg s.c. every 28...
Background : Behavioral and psychological symptoms of dementia (BPSD) are a distressful condition. We aimed to investigate the BPSD distribution in subjects with cognitive impairment, potential correlations between neurodegeneration terms cerebrospinal fluid (CSF) tau brain atrophy. Methods One-hundred patients mild impairment (MCI) or (Alzheimer’s disease, AD; Lewy-body LBD; frontotemporal dementia, FTD; vascular VD) underwent complete diagnostic workup, including 3T-MRI and/or CT CSF....
Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few and with limited follow-up. We aimed to evaluate the long-term (up 52 weeks) effectiveness tolerability of fremanezumab in high-frequency episodic chronic migraine. This s independent, prospective, multicenter cohort study enrolling outpatients 17 Italian Headache Centers or multiple preventive treatment failures. Patients were treated 225 mg monthly. The primary...
Abstract Cognition was assessed in hepatitis C virus (HCV) patients, who did not meet the criteria for a minimal hepatic encephalopathy. Their liver function compensated. We then disentangled potential cognitive changes associated with sustained virologic response at 12 weeks (SVR-12), following treatment direct antiviral agents (DAAs). studied 23 selected HCV patients battery of standard neuropsychological tests, and recordings P300 wave, cerebral “cognitive” significance. There baseline...
Abstract Stroke affects the interconnection between nervous and immune systems, leading to a down-regulation of immunity called stroke-induced immunosuppression (SII). The primary aim this study is investigate SII role as predictor functional, neurological, motor outcomes in neurorehabilitation setting (NRB). We conducted prospective observational enrolling post-acute stroke patients hospitalized for neurorehabilitation. At NRB admission (T 0 ) discharge 1 ), we assessed presence (defined by...
Abstract Background and purpose Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP mAbs) in combination with traditional drugs, scarce data are available on their other mAbs. This study aimed to evaluate 6‐month effectiveness tolerability anti‐CGRP mAbs for different diseases. Methods Patients included Italian Headache Registry treated concomitantly an mAb another were included. Effectiveness outcomes migraine...
Background Migraine with aura (MwA) is a debilitating disorder characterized by paroxysmal attacks of pain preceded or accompanied reversible neurological symptoms. While the pathophysiology remains unclear, trigeminovascular system activation and cortical spreading depression have been implicated. This study aims to comprehensively investigate characterize diverse clinical features manifestations aura, as well types acute medications self-administered for management. Methods A multicenter,...
Preliminary but convergent findings suggest a role for microRNAs (miRNAs) in the generation and maintenance of chronic pain migraine. Initial observations showed that serum levels miR-382-5p miR-34a-5p expression were increased during migraine attack, with increasing interictal phase as well. By contrast, miR-30a-5p lower patients compared to healthy controls. Of note, antimigraine treatments proved be capable influencing these miRNAs. Altogether, miRNAs may represent biomarkers, several...
Abstract Background While migraine is markedly prevalent in women, gender-related phenotype differences were rarely assessed. For this reason, we investigated, through a multicenter observational cross-sectional study, based on an online questionnaire, stress factors, emotions, and pain perception patients controls their impact severity. Methods The study was designed as questionnaire. link emailed to healthy subjects (C) (MIG) (age 18–75, education ≥ 13 years) recruited during the first...